NASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $0.93 -0.04 (-4.35%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$0.95 +0.03 (+2.85%) As of 04/1/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiol Therapeutics Stock (NASDAQ:CRDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's Range$0.88▼$0.9850-Day Range$0.93▼$1.4652-Week Range$0.88▼$3.12Volume203,242 shsAverage Volume386,080 shsMarket Capitalization$76.63 millionP/E RatioN/ADividend YieldN/APrice Target$8.40Consensus RatingBuy Company OverviewCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Read More… Remove Ads Cardiol Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreCRDL MarketRank™: Cardiol Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 549th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cardiol Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiol Therapeutics are expected to grow in the coming year, from ($0.33) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cardiol Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.26% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Cardiol Therapeutics has recently decreased by 5.88%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.26% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Cardiol Therapeutics has recently decreased by 5.88%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.12 News SentimentCardiol Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cardiol Therapeutics this week, compared to 1 article on an average week.Search Interest11 people have searched for CRDL on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.49% of the stock of Cardiol Therapeutics is held by institutions.Read more about Cardiol Therapeutics' insider trading history. Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDL Stock News HeadlinesCardiol Therapeutics Inc. (NASDAQ:CRDL) Given Average Recommendation of "Buy" by BrokeragesMarch 24, 2025 | americanbankingnews.comCardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failureFebruary 20, 2025 | proactiveinvestors.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.April 2, 2025 | Altimetry (Ad)Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation CatalystsFebruary 19, 2025 | seekingalpha.comCardiol Therapeutics initiated with a Buy at Rodman & RenshawJanuary 28, 2025 | markets.businessinsider.comRodman & Renshaw sets $7 target on Cardiol Therapeutics stockJanuary 28, 2025 | msn.comPRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent PericarditisDecember 19, 2024 | globenewswire.comEdward Nash Reaffirms Buy Rating for Cardiol Therapeutics: Positive Phase II Data and Strategic Future Trials Boost Market PotentialNovember 21, 2024 | markets.businessinsider.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at $1.28 at the beginning of the year. Since then, CRDL shares have decreased by 27.5% and is now trading at $0.9276. View the best growth stocks for 2025 here. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) issued its quarterly earnings results on Monday, March, 31st. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings3/31/2025Today4/01/2025Next Earnings (Estimated)4/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDL CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.40 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+805.6%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-194.40% Return on Assets-129.07% Debt Debt-to-Equity Ratio0.01 Current Ratio2.49 Quick Ratio2.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book2.90Miscellaneous Outstanding Shares82,609,000Free Float78,272,000Market Cap$76.63 million OptionableNot Optionable Beta0.95 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:CRDL) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Tax Shock?Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.